Chart pattern: Cup and Handle (daily)
▲ Broken out
Broke on Oct 29, 2026 · measured target $245.32 (+16%). Details →
Nov 5, 6:31 AM ET
Becton, Dickinson and Company announced fourth-quarter fiscal 2026 revenue of $5.3 billion, representing a 5.4% increase as reported compared to the prior-year period. Full-year fiscal 2026 revenue reached $19.5 billion, while the company issued fiscal 2027 guidance projecting GAAP and currency-neutral revenue growth in the low single-digits alongside adjusted diluted EPS of $13.10 to $13.30.
- Q4 revenue grew 5.4% as reported to $5.3 billion, with currency-neutral growth of 5.6%.
- Q4 GAAP diluted EPS was $2.52 and adjusted diluted EPS was $4.15.
- Full-year fiscal 2026 cash from continuing operations increased 30.0% to $3.6 billion and free cash flow rose 42.5% to $2.9 billion.
- Fiscal 2027 guidance projects adjusted diluted EPS between $13.10 and $13.30.
Read the filing on SEC.gov ↗
Aug 6, 6:31 AM ET
BD reported third-quarter fiscal 2026 revenue of $5.0 billion, up 5.4% as reported and 4.4% on a currency-neutral basis, with adjusted diluted EPS from continuing operations of $3.23, up 4.9%. The company raised the midpoint of its full-year adjusted diluted EPS guidance to $12.62 to $12.72 from $12.52 to $12.72 and expects revenue growth toward the high end of its range. Total GAAP diluted EPS fell to $1.37 from $2.00 because of a $74 million loss from discontinued operations.
- Q3 revenue of $4,983 million, up 5.4% as reported from $4,726 million a year earlier
- Adjusted diluted EPS from continuing operations of $3.23 versus $3.08; GAAP continuing-operations EPS of $1.64 versus $1.57
- Total GAAP diluted EPS of $1.37 versus $2.00, including a $74 million loss from discontinued operations
- Fiscal 2026 adjusted diluted EPS guidance updated to $12.62 to $12.72 from $12.52 to $12.72
Read the filing on SEC.gov ↗
Jul 22, 6:58 AM ET
BD said Executive Vice President Michael Garrison, president of the Medical Essentials and BioPharma Systems segments, will retire after more than 20 years with the company. BD is searching for his successor as president of Medical Essentials, and BioPharma Systems will report directly to CEO Tom Polen to streamline the operating model.
- Garrison informed BD of his retirement intention on July 19, 2026, and the press release gives an effective date of Oct. 2.
- The filing says Garrison will stay in his role through the end of the fiscal year to support a smooth transition.
- A comprehensive search is underway for the next president of Medical Essentials.
- BioPharma Systems will report directly to Chairman, CEO and President Thomas E. Polen.
Read the filing on SEC.gov ↗
May 20, 5:05 PM ET
On May 20, 2026, Becton Dickinson's indirect subsidiary Becton Dickinson Euro Finance issued €600 million of 3.855% notes due 2033 in an underwritten public offering, guaranteed by BD. BD said it expects to use the proceeds, with cash on hand, to repay the entire outstanding 1.208% notes due June 4, 2026, with any remainder for general corporate purposes. The filing adds new debt but largely replaces a maturing obligation, so the effect on shareholders is mainly a change in the debt schedule rather than a new use of cash.
- Issued €600 million aggregate principal of 3.855% notes due 2033 on May 20, 2026
- Notes are fully and unconditionally guaranteed on a senior unsecured basis by BD
- Proceeds, with cash on hand, expected to repay the 1.208% notes due June 4, 2026
- Issuer may redeem before February 20, 2033 at the greater of par or a make-whole price plus 15 basis points
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.